RecruitingNot ApplicableNCT05790655

Ovarian PRP for Diminished Ovarian Reserve

Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial


Sponsor

Generation Next Fertility

Enrollment

230 participants

Start Date

Oct 7, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.


Eligibility

Sex: FEMALEMin Age: 35 YearsMax Age: 42 Years

Inclusion Criteria3

  • Clinical diagnosis of diminished ovarian reserve
  • Clinical diagnosis of poor ovarian response
  • Women age 35-42

Exclusion Criteria4

  • Clinical diagnosis of premature ovarian failure
  • Clinical diagnosis of menopause.
  • Under 35 years of age
  • Over 42 years of age

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERoPRP

Prepared sample from patient's own blood collected and processed. Either PRP or serum is injected into the patient's ovary. All other care is standard for the IVF process

OTHERPlacebo- Serum

Patient's serum is injected into ovary instead of PRP as placebo


Locations(1)

Generation Next Fertility

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05790655


Related Trials